The Covid-19 pandemic has been a catalyst for the growth of South Africa’s drug manufacturing industry, as evidenced by Aspen’s new R3 billion sterile manufacturing site in Gqeberha, Eastern Cape.

The pandemic has also highlighted the existing global inequality in access to Covid-19 vaccines, particularly in Africa. What challenges lie ahead in addressing the delivery of high quality affordable medicines in South Africa and on the rest of the continent? What still needs to be done to facilitate this, and what has Covid-19 taught us about Africa’s healthcare needs?

Wits Business School is pleased to invite you to a conversation between Dr Stavros Nicolaou, Senior Executive responsible for Strategic Trade Development at Aspen Pharmacare Group, Africa’s largest pharmaceutical manufacturer.

Dr Nicolaou has over 30 years’ experience in the South African and international pharmaceutical industry. He was instrumental in introducing the first generic ARV’s on the African continent developed by Aspen, which has gone on to save hundreds of thousands of lives. Click here for speaker bio

He will be in conversation with Prof Maurice Radebe, Head and Director of Wits Business School.

Not to be missed!